Onconetix Inc stock rises amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
Source: Benzinga
Onconetix Inc's stock price increased by 18.75% in pre-market trading as it crossed above its 5-day SMA, reflecting strong investor interest.
The rise in Onconetix's stock is amid broader market gains, with the Nasdaq-100 up 0.90% and the S&P 500 up 0.62%. This positive market environment has likely contributed to the stock's upward movement, indicating a favorable sentiment among investors.
As the market continues to show strength, Onconetix's performance may attract further attention, potentially leading to increased trading volume and interest in the company's future developments.
Analyst Views on ONCO
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
